Boehringer Ingelheim has signed up to become a Silver Partner of the World Small Animal Veterinary Association (WSAVA) and will support the work of the association’s Global Pain Council (GPC) and Oncology Working Group (OWG).

The GPC, chaired jointly by Drs Jo Murrell and Paulo Steagall, aims to create a global environment for companion animals in which pain is considered as the fourth vital sign and addressed appropriately. It launched an updated set of Global Guidelines for the Recognition, Assessment and Treatment of Pain at the end of 2022. They are available for free download from the WSAVA website and have also been downloaded xxx times from the JSAP website.

The OWG, chaired by Dr Ann Hohenhaus, is working to overcome regional disparities in the treatment of cancers in dogs and cats by providing continuing education (CE) and a range of additional resources, including fact sheets and an Oncology Glossary, to secure advances in the understanding and treatment of oncology globally.

“Pet ownership is on the rise and many people consider their animal companions to be part of the family. As result, they have high expectations of their veterinarians,” commented Dr Erich Schoett, Head of Global Marketing Pet Therapeutics and Vaccines at Boehringer Ingelheim. “At the same time, small animal medicine is advancing at a staggering pace. Veterinarians face a continuous need to upskill, adapt to new standards of care and to provide tailored health offerings at each stage of a pet’s life.

“We recognize the significant value WSAVA and its committees add to the global veterinary community and are delighted to join with them in fostering standardized, high quality veterinary care for small animals around the world.”

The WSAVA works to advance the health and welfare of companion animals and to advocate on behalf of companion animal veterinarians and the wider veterinary team. Its activities include the development of WSAVA Global Guidelines in key areas of veterinary practice, together with lobbying on important issues affecting companion animal care worldwide.
WSAVA President Dr Ellen van Nierop, said: “It’s thanks to the support of our Industry Partners that we are able to deliver such a wide range of CE to our members and to campaign on the global stage on issues that concern them, such as the global inequity in access to veterinary medicines.

“We’re absolutely delighted to welcome Boehringer Ingelheim as a Silver Partner and thank them very much for their support. We look forward to working with them during 2024 and beyond.”

Note to editors:

About the WSAVA

The WSAVA represents more than 200,000 veterinarians worldwide through its 116 member associations and works to enhance standards of clinical care for companion animals. Its core activities include the development of WSAVA Global Guidelines in key areas of veterinary practice, including pain management, nutrition and vaccination, together with lobbying on important issues affecting companion animal care worldwide.

About Boehringer Ingelheim

Boehringer Ingelheim’s Animal Health business is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, farmers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. As a global leader in the animal health industry and as part of family-owned Boehringer Ingelheim, we take a long-term perspective.

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both. For more information visit: https://www.boehringer-ingelheim.com/animal-health

For further information:

Rebecca George, WSAVA Media Relations

Email: rebecca.george@wsava.org/Phone/WhatsApp +44 7974 161108